Dr. Behrens has served as a member of our board of directors since January 2019. Since December 2009, Dr. Behrens has served as an independent life sciences consultant and investor. From January 2012 to June 2014, she served as the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. From 1996 to December 2009, Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a General Partner for selected venture funds. Prior to this, from 1983 to 1996, she served as a General Partner and Managing Director at Robertson Stephens & Co. Since March 2009, Dr. Behrens has served as a member of the board of directors of Sarepta Therapeutics, a medical research and drug development company, and as Chairwoman since April 2015, as well as Chair of its audit committee and a member of its research and development committee. She has served as Chairwoman of the board of directors of MiMedx Group, a biomedical company, since June 2019, and as a member of its nominating and governance committee and audit committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. She previously served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. She has also spent time as a public-market biotechnology securities analyst and a venture capitalist focusing on healthcare, technology and related investments. She also previously served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.

Dr. Hambleton has served as a member of our board of directors since August 2018. Dr. Hambleton served as Interim President & CEO, Arch Oncology, a private company, from August 2020 to March 2021. From June 2018 until her retirement in April 2020, Dr. Hambleton served as Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, an oncology medicine company. From September 2017 to May 2018 and from March 2016 to May 2016, Dr. Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017, she served as Vice President, Head U.S. Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016, Dr. Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012, Dr. Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010, Dr. Hambleton held increasing roles of responsibility in BioOncology at Genentech. Dr. Hambleton has served on the board of directors of SpringWorks Therapeutics, a biopharmaceutical company, since May 2020 and Erasca, Inc., a biotechnology company, since March 2021. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr. Hambleton received an M.D. from Case Western Reserve University School of Medicine and a B.S. in Nursing from Duke University and was board-certified in Hematology and Internal Medicine.

Mr. Lee has served as a member of our board of directors since July 2019. Mr. Lee has served as Co-Founder and Portfolio Manager at Redmile Group, an investment advisory firm since 2007. Prior to Redmile, Mr. Lee worked as a biotechnology investor at Steeple Capital, an investment management firm, and as an analyst at Welch Capital Partners, an investment advisory firm, and Prudential Equity Group, a financial services company. Mr. Lee has served on the board of directors of Fate Therapeutics, a biopharmaceutical company, since July 2018 and Shattuck Labs, a biotechnology company, since June 2020. Mr. Lee holds a B.S. in Molecular and Cellular Biology from the University of Arizona.

Mr. Schwarzer has served as our Chief Executive Officer since July 2010 and has been a member of our board of directors since February 2003, serving as Chairman until August 2018. Mr. Schwarzer has also served as our President since December 2018, and previously served as Chief Executive Officer and President at different times between December 1999 and May 2003. Mr. Schwarzer was a founder of Charter Life Sciences, a venture capital firm specializing in life sciences investments, in 2003 and served as its Managing Partner from inception until August 2019. Mr. Schwarzer previously served as Chair of the board of directors of Inviragen, a biopharmaceutical company and developer of the DENVax dengue vaccine, from 2009 until Inviragen’s acquisition by Takeda Pharmaceutical Company in 2013. He also served as Chief Executive Officer and Chairman of the board of directors of Heska Corporation, a biotechnology company focused primarily on the animal healthcare markets, from 1994 to 1998 and 1999 to 2001, respectively. Mr. Schwarzer received a B.A in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California, Berkeley, School of Law.

Dr. Strohl has served as a member of our board of directors since August 2018. In August 2016, Dr. Strohl founded BiStro Biotech Consulting, a biotechnology consulting company, of which he also serves as President. From February 2016 to August 2016, Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, a multinational medical devices and pharmaceutical company, and served as its Vice President and Head from October 2013 to February 2016. Prior to that, from April 2008 to October 2013, Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl has also held various roles at Merck, a pharmaceutical company, including leading Natural Products Biology and leading Biologics discovery efforts and was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University.

Dr. Thompson has served as a member of our board of directors since October 2023. Dr. Thompson is currently Executive Vice President of Research and Development, Rare Disease at Amgen.  At the time of its acquisition by Amgen, Dr. Thompson served as the Executive Vice President of Research and Development of Horizon Therapeutics. During her time at Horizon, Dr. Thompson played an important role in the transformation of Horizon into a science-based biopharma company, establishing and growing an R&D function comprising scientists and technical experts across research, translational sciences, clinical development, clinical operations, biometrics, PV and safety, regulatory affairs, project and program management, R&D strategy and external innovation. She also played a key role in the acquisition and integration of Viela Bio as well as the expedited filing and approval of TEPEZZA®, including its successful FDA Advisory Committee meeting. Prior to Horizon, Dr. Thompson held roles of increasing seniority and scope at AbbVie, Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications. Dr. Thompson has served as a member of the board of California Life Sciences, a life sciences membership organization and was named to the PharmaVoice 100 list in 2023 and the Healthcare Businesswomen’s Association Luminary list in 2021.  Dr. Thompson received a Ph.D. in Macromolecular and Cellular Structure and Chemistry from the Scripps Research Institute and a B.S. in Chemistry from Harvey Mudd College.

 

Ms. Topsøe has served as a member of our board of directors since August 2018, and previously served as an observer on our board of directors beginning in 2013. Since March 2013, Ms. Topsøe has served on the board of directors of Haldor Topsøe A/S, and has served on the board of directors of Topsøe Holding A/S, its holding company, since June 2015. Ms. Topsøe previously was a lawyer at Allen & Overy LLP and Simpson Thacher and Bartlett LLP. Ms. Topsøe pursued a B.A. in Chinese Studies from the University of Copenhagen, studied Chinese Language and Literature at Peking University, and received an LL.B. from the University of London and an M.B.A. from London Business School and Columbia Business School.

Mr. Topsøe has served as a member of our board of directors since August 2018. Since June 2015, Mr. Topsøe has served as Chairman of the board of directors of Topsøe Holding A/S, and has served on the board of directors of Haldor Topsøe A/S, a Danish catalysis and chemical processing company and a subsidiary of Topsøe Holding A/S, since October 2010 and as its Vice Chairman since August 2016. Since January 2009, Mr. Topsøe has served as Partner at AMBROX Capital, a Danish investment management firm, and as Associate Partner since September 2016. From 1996 to 2008, Mr. Topsøe was employed in various functions within Alfred Berg/ABN Amro Bank including Head of Equities, Denmark. Mr. Topsøe served as a member of the board of directors of Motortramp, a Danish provider of marine transportation services, and Dampskibsselskabet Orients Fond, a Danish charitable foundation, from 2017 to October 2020. Mr. Topsøe received a Graduate Diploma in Business Administration (Finance) from the Copenhagen Business School.

Dr. Ahmed is a virologist and immunologist, and an internationally recognized expert on T cell survival, function and the development of immunological memory. He is a Director of the Emory Vaccine Center; Charles Howard Candler Professor of Microbiology and Immunology, Emory University School of Medicine. His work includes discoveries related to how immune memory cells are created, how long they survive and how factors such as IL-2 and IL-15 relate to these responses within different microenvironments within an organism and the relationship between chronic viral infection and ongoing immunity. His work impacts the development of therapeutics in infectious disease, particularly in the setting of viral infection and viral persistence to cancer and cancer immunology. Dr. Ahmed is the author or co-author of more than 300 peer-reviewed articles, has received numerous awards, including the William B. Coley Award in 2017 and is a member of the National Academy of Sciences. Dr. Ahmed received his Ph.D. degree in microbiology from Harvard University. Before coming to Emory, he was a Professor at the University of California, Los Angeles School of Medicine.

Dr. Davis is one of the world’s leading authorities on T cell recognition. His research focuses on how T cells and B cells recognize antigen and behave following such interactions. This includes the structural and biochemical underpinnings of T cell receptor binding and signal transduction and the dynamics of molecular movement at the T cell/antigen-presenting cell interface, in both preclinical models and humans. His discoveries include identifying the T-cell receptor gene, development of peptide-MHC tetramers to study T cell populations capable of recognizing particular targets and elucidation and quantification of specific events at the immunologic synapse required for T cell function. Dr. Davis is the author or co-author of more than 300 peer-reviewed articles and books, is a member of the National Academy of Sciences, and is the recipient of numerous awards and distinctions, including the William B. Coley Award in 2000. Dr. Davis received his B.A. degree in molecular biology from Johns Hopkins University and his Ph.D. degree in molecular biology from the California Institute of Technology. He was a postdoctoral fellow at the Laboratory of Immunology at the National Institutes of Health prior to joining Stanford.